NasdaqGS - Delayed Quote USD
Roivant Sciences Ltd. (ROIV)
11.23
+0.03
+(0.27%)
At close: June 6 at 4:00:00 PM EDT
11.50
+0.27
+(2.43%)
After hours: June 6 at 7:37:04 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2026) | Next Year (2027) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 4 |
| Avg. Estimate | -0.23 | -0.25 | -1.01 | -1.25 |
| Low Estimate | -0.29 | -0.3 | -1.22 | -1.4 |
| High Estimate | -0.18 | -0.2 | -0.81 | -1.06 |
| Year Ago EPS | -0.18 | -0.3 | -0.86 | -1.01 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2026) | Next Year (2027) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 7 |
| Avg. Estimate | 7.16M | 7.26M | 29.24M | 37.32M |
| Low Estimate | 1.78M | 1.78M | 7.12M | -- |
| High Estimate | 15M | 15M | 60M | 112M |
| Year Ago Sales | 55.13M | 29.26M | 29.05M | 29.24M |
| Sales Growth (year/est) | -87.02% | -75.20% | 0.63% | 27.66% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.24 | -0.24 | -0.24 | -0.16 |
| EPS Actual | -0.18 | -0.3 | -0.2 | -0.22 |
| Difference | 0.06 | -0.06 | 0.04 | -0.05 |
| Surprise % | 25.67% | -23.75% | 17.17% | -33.65% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2026) | Next Year (2027) |
|---|---|---|---|---|
| Current Estimate | -0.23 | -0.25 | -1.01 | -1.25 |
| 7 Days Ago | -0.25 | -0.26 | -0.92 | -1.15 |
| 30 Days Ago | -0.25 | -0.26 | -0.92 | -1.15 |
| 60 Days Ago | -0.25 | -0.26 | -0.92 | -1.15 |
| 90 Days Ago | -0.25 | -0.26 | -0.92 | -1.15 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2026) | Next Year (2027) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | 1 | 1 | 1 | 4 |
| Down Last 30 Days | 1 | 1 | 1 | 4 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ROIV | -28.92% | 16.95% | -17.05% | -24.67% |
| S&P 500 | 13.13% | 2.48% | 7.55% | 14.01% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/28/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/21/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/11/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 9/19/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/19/2024 |
Related Tickers
IMVT Immunovant, Inc.
16.77
+4.68%
ABUS Arbutus Biopharma Corporation
3.4800
+2.35%
NUVL Nuvalent, Inc.
78.02
-0.09%
CYTK Cytokinetics, Incorporated
32.30
+0.69%
TLX Telix Pharmaceuticals Limited
16.77
-3.40%
CNTA Centessa Pharmaceuticals plc
11.92
+0.51%
RPRX Royalty Pharma plc
33.78
+0.09%
RVMD Revolution Medicines, Inc.
41.09
+2.21%
GMAB Genmab A/S
22.20
+1.79%
RARE Ultragenyx Pharmaceutical Inc.
37.17
+0.69%